中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2011年
2期
267-270
,共4页
陈创奇%方乐堃%蔡世荣%马晋平%何裕隆
陳創奇%方樂堃%蔡世榮%馬晉平%何裕隆
진창기%방악곤%채세영%마진평%하유륭
心脏移植%免疫调节%T细胞
心髒移植%免疫調節%T細胞
심장이식%면역조절%T세포
Heart transplantation%Immunoregulation%T cell
目的 观察CD4+CD25+T细胞(Treg)对小鼠同种异体心脏移植的免疫调节作用.方法 流式细胞仪检测正常小鼠和胸腺切除+PC61小鼠淋巴结、脾脏和外周血的Treg的比例.将供体鼠BALB/C心脏移植到受体鼠B6腹腔内,观察对照组(n=6)、胸腺切除组(THY,n=8)、hCTLA4Ig组(n=8)、DST+hCTLA4Ig组(n=8)和THY+PC61+DST+hCTLA4Ig组(n=6)小鼠心脏移植后生存时间和移植心脏病理学检查.结果 正常B6小鼠淋巴结、脾脏和外周血的Treg的比例分别为5.1%、4.5%和1. 7%,明显高于胸腺切除+PC61处理组(1. 8%、1.7%、0.7%).移植心脏平均存活时间在对照组和胸腺切除组分别为(8.2±2.9)d和(7.6±3.0)d,两组间差异无统计学意义(P>0.05);而在hCTLA4Ig组和DST+hCTLA4Ig组分别为(43.0±11.8)d和(135.0±29.7)d,均较对照组或胸腺切除组明显延长(P<0.01);THY+PC61+DST+hCTLA4Ig组移植心脏平均存活时间(25.8±8.9)d,也明显较对照组明显延长,但短于hCTLA4Ig组和DST+hCTLA4Ig组(P<0.01).DST+hCTLA4Ig组移植的心脏存活时间(135.0±29.7)d明显高于其他各组(P<0.01),其病理组织学表现为间质内有较多的淋巴细胞浸润,伴毛细血管增生,管壁增厚,间质纤维化.结论 CD4+CD25+T细胞水平对同种异体心脏移植的免疫耐受具有免疫调节作用.
目的 觀察CD4+CD25+T細胞(Treg)對小鼠同種異體心髒移植的免疫調節作用.方法 流式細胞儀檢測正常小鼠和胸腺切除+PC61小鼠淋巴結、脾髒和外週血的Treg的比例.將供體鼠BALB/C心髒移植到受體鼠B6腹腔內,觀察對照組(n=6)、胸腺切除組(THY,n=8)、hCTLA4Ig組(n=8)、DST+hCTLA4Ig組(n=8)和THY+PC61+DST+hCTLA4Ig組(n=6)小鼠心髒移植後生存時間和移植心髒病理學檢查.結果 正常B6小鼠淋巴結、脾髒和外週血的Treg的比例分彆為5.1%、4.5%和1. 7%,明顯高于胸腺切除+PC61處理組(1. 8%、1.7%、0.7%).移植心髒平均存活時間在對照組和胸腺切除組分彆為(8.2±2.9)d和(7.6±3.0)d,兩組間差異無統計學意義(P>0.05);而在hCTLA4Ig組和DST+hCTLA4Ig組分彆為(43.0±11.8)d和(135.0±29.7)d,均較對照組或胸腺切除組明顯延長(P<0.01);THY+PC61+DST+hCTLA4Ig組移植心髒平均存活時間(25.8±8.9)d,也明顯較對照組明顯延長,但短于hCTLA4Ig組和DST+hCTLA4Ig組(P<0.01).DST+hCTLA4Ig組移植的心髒存活時間(135.0±29.7)d明顯高于其他各組(P<0.01),其病理組織學錶現為間質內有較多的淋巴細胞浸潤,伴毛細血管增生,管壁增厚,間質纖維化.結論 CD4+CD25+T細胞水平對同種異體心髒移植的免疫耐受具有免疫調節作用.
목적 관찰CD4+CD25+T세포(Treg)대소서동충이체심장이식적면역조절작용.방법 류식세포의검측정상소서화흉선절제+PC61소서림파결、비장화외주혈적Treg적비례.장공체서BALB/C심장이식도수체서B6복강내,관찰대조조(n=6)、흉선절제조(THY,n=8)、hCTLA4Ig조(n=8)、DST+hCTLA4Ig조(n=8)화THY+PC61+DST+hCTLA4Ig조(n=6)소서심장이식후생존시간화이식심장병이학검사.결과 정상B6소서림파결、비장화외주혈적Treg적비례분별위5.1%、4.5%화1. 7%,명현고우흉선절제+PC61처리조(1. 8%、1.7%、0.7%).이식심장평균존활시간재대조조화흉선절제조분별위(8.2±2.9)d화(7.6±3.0)d,량조간차이무통계학의의(P>0.05);이재hCTLA4Ig조화DST+hCTLA4Ig조분별위(43.0±11.8)d화(135.0±29.7)d,균교대조조혹흉선절제조명현연장(P<0.01);THY+PC61+DST+hCTLA4Ig조이식심장평균존활시간(25.8±8.9)d,야명현교대조조명현연장,단단우hCTLA4Ig조화DST+hCTLA4Ig조(P<0.01).DST+hCTLA4Ig조이식적심장존활시간(135.0±29.7)d명현고우기타각조(P<0.01),기병리조직학표현위간질내유교다적림파세포침윤,반모세혈관증생,관벽증후,간질섬유화.결론 CD4+CD25+T세포수평대동충이체심장이식적면역내수구유면역조절작용.
Objective To investigate the immunoregulation effects of CD4 + CD25 + T cells in mice heart allograft transplantation. Methods Flow cytometry was used to analyze the contents of CD4 + CD25 +T regulatory cells (Tregs) of the lymph nodes, spleen and blood in the normal mice group and the thymusectomy (THY) + PC61 group. BALB/C mice served as the donors and C57BL/6 (B6) mice as the recipients. Five groups were established, including control group ( n = 6 ), THY group ( n = 8 ), hCTLA4Ig group ( n = 8 ), DST ( donor-specific T-depleted spleen cells) + hCTLA4Ig group ( n = 8) and THY + PC61+ DST + hCTLA4Ig group (n = 6). The survival time after heart allograft transplantation was observed and pathological examination was done in different groups. Results In control group, the rate of Tregs in lymph nodes, spleen and blood was 5. 1%, 4. 5% and 1.7% respectively, which was significantly higher than in THY + PC61 group ( 1. 8% , 1. 7% and 0. 7% respectively). The average survival time of control and THY groups was 8. 2 ± 2.9 and 7.6 ± 3. 0 days respectively ( P > 0. 05 ). The average survival time of hCTLA4Ig and DST + hCTLA4Ig groups was 43.0 ± 11.8 and 135.0 ± 29. 7 days respectively, which was significantly longer than in control group or THY group ( P <0. 01 ). The average survival time of THY +PC61 + DST + hCTLA4Ig group was 25.8 ± 8.9 days, which was significantly longer than in control group,but shorter than in hCTLA4Ig group or DST + hCTLA4Ig group ( P < 0. 01 ). The survival time in DST +hCTLA4Ig group was 135.0 ± 29. 7 days, which was significantly longer than other groups ( P < 0. 01 ).The pathological examination revealed that there were more lymphocytes infiltration and capillary vessel proliferation in the desmohemoblast in the transplanted heart of DST + hCTLA4Ig group. Conclusion CD4 +CD25 +T cells regulate the immune tolerance in the allograft transplantation.